These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
341 related articles for article (PubMed ID: 8619397)
1. Bedside measurement of factor VIII:C activity in individuals with hemophilia A. Kessler CM; Bernstein Z; Ghesani S; Shamsipour Z; Frances C; Zucker ML; LaDuca FM Am J Hematol; 1996 Mar; 51(3):181-5. PubMed ID: 8619397 [TBL] [Abstract][Full Text] [Related]
2. The utility of activated partial thromboplastin time (aPTT) clot waveform analysis in the investigation of hemophilia A patients with very low levels of factor VIII activity (FVIII:C). Shima M; Matsumoto T; Fukuda K; Kubota Y; Tanaka I; Nishiya K; Giles AR; Yoshioka A Thromb Haemost; 2002 Mar; 87(3):436-41. PubMed ID: 11916076 [TBL] [Abstract][Full Text] [Related]
3. [The effect of factor VIII:C activity on the activated partial thromboplastin time (aPTT) in the dog. Adaptation of the aPTT as a screening test for canine hemophilia A?]. Mischke R Dtsch Tierarztl Wochenschr; 1993 Jun; 100(6):219-22. PubMed ID: 8339706 [TBL] [Abstract][Full Text] [Related]
4. [Comparison of factor VIII:C and factor IX sensitivity of different commercial APTT reagents for canine plasma]. Mischke R Berl Munch Tierarztl Wochenschr; 1999; 112(10-11):394-9. PubMed ID: 10598358 [TBL] [Abstract][Full Text] [Related]
5. Activated partial thromboplastin time. A multicenter evaluation of 11 reagents in the screening of mild haemophilia A. Scand J Haematol; 1980 Oct; 25(4):308-17. PubMed ID: 6782653 [TBL] [Abstract][Full Text] [Related]
6. Studies of phospholipid reagents used in coagulation I: some general properties and their sensitivity to factor VIII. Barrowcliffe TW; Gray E Thromb Haemost; 1981 Oct; 46(3):629-33. PubMed ID: 6797093 [TBL] [Abstract][Full Text] [Related]
7. Lyophilised plasmas for one-stage determination of factor VIII. Sikorová J; Vorlová Z Folia Haematol Int Mag Klin Morphol Blutforsch; 1980; 107(6):906-13. PubMed ID: 6162757 [TBL] [Abstract][Full Text] [Related]
8. Measurement of factor VIII activity using one-stage clotting assay: a calibration curve has not to be systematically included in each run. Lattes S; Appert-Flory A; Fischer F; Jambou D; Toulon P Haemophilia; 2011 Jan; 17(1):139-42. PubMed ID: 20731727 [TBL] [Abstract][Full Text] [Related]
9. [Effect of substrate and diluent for factor VIII activity in highly purified factor VIII concentrate and patient plasma infused factor VIII concentrate]. Takahashi I; Furuta M; Mizuno S; Takamatsu J; Kamiya T Rinsho Byori; 1993 Jul; 41(7):825-30. PubMed ID: 8361054 [TBL] [Abstract][Full Text] [Related]
10. Issues with the assay of factor VIII activity in plasma and factor VIII concentrates. Lundblad RL; Kingdon HS; Mann KG; White GC Thromb Haemost; 2000 Dec; 84(6):942-8. PubMed ID: 11154139 [TBL] [Abstract][Full Text] [Related]
11. Functional activated protein C resistance assays: correlation with factor V DNA analysis is better with RVVT-than APTT-based assays. Favaloro EJ; Mirochnik O; McDonald D Br J Biomed Sci; 1999; 56(1):23-33. PubMed ID: 10492912 [TBL] [Abstract][Full Text] [Related]
12. In vitro kinetics of factor VIII activity in patients with mild haemophilia A and a discrepancy between one-stage and two-stage factor VIII assay results. Rodgers SE; Duncan EM; Barbulescu DM; Quinn DM; Lloyd JV Br J Haematol; 2007 Jan; 136(1):138-45. PubMed ID: 17222201 [TBL] [Abstract][Full Text] [Related]
13. Validation of a procedure for potency assessing of a high purity factor VIII concentrate--comparison of different factor VIII coagulant assays and effect of prediluent. Mazurier C; Parquet-Gernez A; Goudemand M Thromb Haemost; 1990 Oct; 64(2):251-5. PubMed ID: 2125374 [TBL] [Abstract][Full Text] [Related]
14. Evaluation of coagulometric assays in the assessment of protein C anticoagulant activity; variable sensitivity of commercial APTT reagents to the cofactor effect of protein S. D'Angelo SV; Gilardoni F; D'Angelo A Thromb Haemost; 1989 Nov; 62(3):861-7. PubMed ID: 2531939 [TBL] [Abstract][Full Text] [Related]
15. [Activated partial thromboplastin time. Evaluation of sensitivity and validity for determination of factor VIII coagulant activity]. Camici M; Evangelisti L Minerva Med; 1993 Feb; 84(1-2):11-6. PubMed ID: 8464562 [TBL] [Abstract][Full Text] [Related]
16. Factor VIII inhibitors. Laboratory diagnosis of inhibitors. Sahud MA Semin Thromb Hemost; 2000; 26(2):195-203. PubMed ID: 10919413 [TBL] [Abstract][Full Text] [Related]
17. Freeze-dried activated substrate for factor VIII assays. Margolis J Dev Biol Stand; 1987; 67():163-7. PubMed ID: 3111909 [TBL] [Abstract][Full Text] [Related]
18. A detailed comparison of the performance of the standard versus the Nijmegen modification of the Bethesda assay in detecting factor VIII:C inhibitors in the haemophilia A population of Canada. Association of Hemophilia Centre Directors of Canada. Factor VIII/IX Subcommittee of Scientific and Standardization Committee of International Society on Thrombosis and Haemostasis. Giles AR; Verbruggen B; Rivard GE; Teitel J; Walker I Thromb Haemost; 1998 Apr; 79(4):872-5. PubMed ID: 9569207 [TBL] [Abstract][Full Text] [Related]
19. Comparative analysis of chromogenic vs clot.based one stage APTT assay for determination of factor VIII level. Baig MA; Swamy KB Indian J Pathol Microbiol; 2021; 64(1):123-127. PubMed ID: 33433421 [TBL] [Abstract][Full Text] [Related]
20. Noncitrated whole blood is optimal for evaluation of postinjury coagulopathy with point-of-care rapid thrombelastography. Kashuk JL; Moore EE; Le T; Lawrence J; Pezold M; Johnson JL; Cothren CC; Biffl WL; Barnett C; Sabel A J Surg Res; 2009 Sep; 156(1):133-8. PubMed ID: 19577246 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]